CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-04-01): Adenoviral transfer of angiostatin-like molecule inhibits tumor growth in mice

Science

Adenoviral transfer of angiostatin-like molecule inhibits tumor growth in mice

Last Updated: 2004-04-01 10:13:06 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Angiostatic gene transfer produces tumor and protein-specific effects against carcinomas in mice.

In the April issue of Gut, Dr. C. Qian and colleagues at the University of Navarro in Pamplona, Spain describe experiments in which recombinant adenoviruses encoding angiostatin-like molecule or endostatin were injected into mice with hepatocellular carcinoma, colorectal carcinoma, or lung carcinoma.

Treatment with angiostatin-like molecule, but not treatment with endostatin, significantly inhibited endothelial cell infiltration in mice.

In immune competent mice with lung carcinoma, both proteins had similar antitumor effects, but in athymic mice with lung tumors, the effect of angiostatin-like molecule was stronger.

Angiostatin-like molecule also inhibited tumor growth in a murine model of colorectal carcinoma. Furthermore, the researchers report, angiostatin-like molecule also reduced tumor progress in a model of human hepatocellular carcinoma.

However, endostatin did not inhibit tumor growth in either the murine model of colorectal carcinoma or the human hepatocellular carcinoma model.

"Our data demonstrate that angiostatic gene therapy may form a feasible strategy for the treatment of established hepatocellular carcinomas," the researchers conclude.

They add, "Tumor and protein specificity of angiostatic tumor therapies is a striking aspect as tumor angiogenesis is considered to be a common pathological process independent of tumor type. Our findings indicate that different tumor entities have to be specifically evaluated for antitumor responsiveness towards distinct angiostatic proteins."

Gut 2004;53:561-567

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.